

Investment Rational

75% of clinical trials fail due to lack of efficacy and safety, costing pharma over \$50B in wasted spend each year. QuantHealth's in-silico engine solves this by combining proprietary preclinical and clinical data to learn deep drug-patient interactions and to predict real-world patient outcomes to novel and approved therapies, in order to enhance trial design and development strategy.

Business Strategy

QuantHealth can identify which companies will benefit from our solution ahead of time. We help them increase trial success rates, reduce development spend, while driving increased revenues.

Core Technology

We developed an AI platform that combines disparate and proprietary datasets across the drug development pipeline to predict how individual patients will respond to a drug of interest in the real world.

Product Profile/Pipeline

We are helping several small-mid pharma companies, plan their phase II-III clinical trials for previously approved therapies. We are now honing our ability to conduct phase-I simulations for new drugs, and will be able to conduct clinical simulations for drugs in discovery by Q3 2022.

Main Service:

We work with clinical development teams within pharma, and are expanding into CROs, preclinical, and discovery. We are operational in hemato-oncology and immune, and are expanding into oncology, neurology and other TAs.

Key Strengths:

We are the only product that predicts how early stage therapeutics will work in real patients. We combine proprietary clinical and preclinical datasets leveraging our proprietary AI engine. Our team consists of highly skilled data scientists, professors, clinicians, and industry experts.

Key Markets:

Our customers are primarily in the EU and USA. Our technology is more advantageous to companies developing their drugs in the US, given our US-based clinical datasets. However, in clinical areas where the biology is consistent across geographies, our services are relevant globally.